8-K: Edgewell Reports Mixed FY25, Divests Feminine Care

Edgewell Personal Care announced its fourth quarter and fiscal year 2025 results, revealing mixed performance with a net sales decrease for the full year but organic growth in Q4, alongside the strategic divestiture of its Feminine Care business and a new share repurchase authorization.

Summary

• Fourth quarter 2025 net sales increased 3.8% to $537.2 million, with organic net sales growing 2.5%.
• Fiscal year 2025 net sales decreased 1.3% to $2,223.5 million, with organic net sales also decreasing 1.3%.
• GAAP Diluted EPS for Q4 2025 was a loss of $(0.66), while Adjusted EPS was $0.68.
• GAAP EPS for fiscal year 2025 was $0.53, and Adjusted EPS was $2.52, inclusive of a $0.48 unfavorable impact from currency movements.
• The company recorded a non-cash goodwill impairment charge of $51.1 million in Q4 for the Feminine Care reporting unit due to its planned divestiture.
• International markets delivered organic growth of 6.9% in Q4 and 3.5% for the full fiscal year.
• North America organic sales declined 0.6% in Q4 and 4.4% for the full fiscal year.
• Net cash provided by operating activities for fiscal 2025 was $118.4 million, a decrease from $231.0 million in the prior year.
• Edgewell returned $119.5 million to shareholders in fiscal year 2025 through $90.2 million in share repurchases and $29.3 million in dividends.
• The company ended Q4 with $225.7 million in cash on hand and a net debt leverage ratio of 3.9x.
• A definitive agreement was reached to sell the Feminine Care business to Essity for $340 million.
• For fiscal year 2026, reported net sales are expected to increase 0.5% to 3.5%, with organic net sales ranging from a 1% decrease to a 2% increase (outlook does not reflect Feminine Care divestiture).
• Fiscal year 2026 Adjusted EPS is expected to be in the range of $2.15 to $2.55, and Adjusted EBITDA is projected between $290 million and $310 million.

Sentiment

Score: 4

Explanation: The company's fiscal 2025 performance was weak, marked by declining sales, a significant drop in GAAP EPS, and a goodwill impairment. However, the strategic divestiture of the Feminine Care business for $340 million, coupled with a new $100 million share repurchase authorization and a commitment to return to organic sales growth in FY2026, suggests a clear path towards refocusing and potential future value creation. The Q4 organic sales growth and international market strength provide some positive momentum, but overall results are mixed with significant challenges.

Positives

• Fourth quarter net sales increased 3.8% to $537.2 million, with organic net sales up 2.5%.
• International markets demonstrated durable organic growth of 6.9% in Q4 and 3.5% for the full fiscal year, driven by volume and price gains.
• The company returned $119.5 million to shareholders in fiscal year 2025 through $90.2 million in share repurchases and $29.3 million in dividends.
• A new share repurchase authorization for up to $100 million was issued by the Board of Directors.
• The definitive agreement to sell the Feminine Care business for $340 million is a strategic move to transform Edgewell into a more focused and agile personal care company.
• The company exited fiscal 2025 with encouraging momentum, marked by improving sales and market share trends and a revitalized brand portfolio.
• Fiscal 2026 outlook anticipates a return to organic sales growth (up to 2% increase) and an approximate 60-basis point increase in adjusted gross margin.

Negatives

• Fiscal year 2025 net sales decreased 1.3% to $2,223.5 million, with organic net sales also declining 1.3%.
• Fiscal year 2025 GAAP EPS significantly decreased to $0.53 from $1.97 in the prior year.
• Fourth quarter 2025 GAAP Diluted EPS was a loss of $(0.66).
• A non-cash goodwill impairment charge of $51.1 million was recorded in Q4 for the Feminine Care reporting unit.
• Q4 gross margin decreased 230-basis points to 38.8%, and adjusted gross margin decreased 330-basis points to 39.3%.
• Q4 adjusted operating income decreased to $40.3 million from $56.0 million in the prior year quarter.
• North America organic sales declined 0.6% in Q4 and 4.4% for the full fiscal year.
• Segment profit saw significant decreases in Q4: Wet Shave (14.8%), Sun and Skin Care (64.3%), and Feminine Care (22.6%).
• Net cash provided by operating activities for fiscal 2025 decreased significantly to $118.4 million from $231.0 million in the prior year.
• The fiscal 2026 outlook projects an approximate 50-basis point decrease in adjusted operating margin due to higher A&P investment and increased SG&A expense.
• The company's net debt leverage ratio stood at 3.9x at the end of Q4 2025.

Risks

• Ability to compete in products, prices, and costs within an intensely competitive industry.
• Potential loss of principal customers or changes in their policies.
• Inability to design and execute a successful omnichannel strategy.
• Fluctuations in the price and supply of raw materials and costs of labor, warehousing, and transportation.
• Impact of seasonal volatility on sales, financial performance, working capital requirements, and cash flow.
• Ability to successfully manage evolving global financial risks, including tariffs, foreign currency fluctuations, currency exchange or pricing controls, and localized volatility.
• Level of indebtedness and the various covenants related thereto, and ability to generate sufficient income and cash flow.
• Failure to maintain brand reputation and successfully respond to changing consumer habits and perceptions.
• Access to capital markets and borrowing capacity.
• Impairment of goodwill and other intangible assets (as seen with the Feminine Care unit).
• Ability to successfully manage financial, legal, reputational, and operational risks associated with third-party relationships.
• Risks associated with international operations.
• Ability to effectively integrate acquired companies and successfully manage divestiture activities.
• Ability to successfully implement cost savings initiatives, including rationalization or restructuring efforts.
• Reliance on and maintenance of key Company and third-party information and operational technology systems, networks, and services.
• Ability to successfully achieve, maintain, or adjust environmental or sustainability goals and priorities.
• Ability to successfully manage current and expanding regulatory and legal requirements and matters.
• Ability to adequately protect intellectual property rights.
• Product quality and safety issues, including recalls and product liability.
• Losses or increased funding and expenses related to pension plans.
• Macroeconomic factors, including supply chain disruptions, tariffs, and inflationary pressures.

Future Outlook

The company forecasts reported net sales to increase by 0.5% to 3.5% in fiscal 2026, with organic net sales ranging from a 1% decrease to a 2% increase. Adjusted EPS is projected between $2.15 and $2.55. Management expects adjusted gross margin to increase by approximately 60-basis points, but adjusted operating margin is anticipated to decrease by about 50 basis points due to higher brand investment and SG&A. The outlook does not yet reflect the planned divestiture of the Feminine Care business, and adjustments will be provided post-close of the transaction. The company expects to incur approximately $49 million in pre-tax restructuring charges in fiscal 2026.

Management Comments

• "Fiscal 2025 was a year of challenge and transformation. While both external and internal pressures impacted our results, we exited the year with encouraging momentum—marked by improving sales and market share trends and a revitalized brand portfolio."
• "International markets continued to deliver durable growth, we made meaningful strides in driving further productivity and advanced our innovation agenda with consumer-led launches across key regions."
• "As we enter fiscal 2026, we're focused on execution, margin recovery, and delivering sustainable shareholder value. Importantly, we believe Edgewell now has the team, structure, and capabilities in place to return to organic sales growth in 2026, with accelerated growth in the second half of 2026 and into 2027."
• "Our decision to divest the Feminine Care business marks a pivotal step in transforming Edgewell into a more focused, agile and consumer-driven personal care company."

Industry Context

The personal care industry is characterized by intense competition, evolving consumer preferences, and macroeconomic pressures such as inflation and currency fluctuations. Edgewell's strategic divestiture of its Feminine Care business and its focus on productivity, innovation, and streamlining operations align with broader industry trends where companies are optimizing portfolios and operational efficiencies to enhance shareholder value. The company's stronger performance in international markets compared to North America highlights regional variations in market dynamics and consumer demand within the global personal care sector.

Corporate Governance

Stakeholder Impact

• Shareholders will receive a quarterly dividend of $0.15 per share and benefit from the new $100 million share repurchase authorization, indicating a commitment to shareholder returns. The Feminine Care divestiture aims for long-term value creation, but the goodwill impairment reflects a past asset value reduction. Mixed financial results for FY25 may impact investor confidence.
• Employees may be impacted by restructuring and repositioning actions, including the consolidation of Mexico operations and further consolidation of Wet Shave operations, which involve severance and other exit costs.
• Customers may benefit from the company's innovation agenda and consumer-led launches, as well as increased promotional levels in Sun & Skin Care.
• Creditors will note the net debt leverage ratio of 3.9x and the company's access to its revolving credit facility. Proceeds from the divestiture could be used to manage debt.

Next Steps

• Close the definitive agreement to sell the Feminine Care business to Essity.
• Provide adjustments to the 2026 financial outlook post-close of the Feminine Care transaction.
• Focus on execution, margin recovery, and delivering sustainable shareholder value in fiscal 2026.
• Implement specific actions to strengthen the operating model, simplify the organization, and improve manufacturing and supply chain efficiency through restructuring and repositioning actions, including further consolidation of Wet Shave operations.
• Pay a cash dividend of $0.15 per common share on January 8, 2026, to shareholders of record on December 4, 2025.
• Utilize the new $100 million share repurchase authorization.

Key Dates

Recommendation

The company's fiscal 2025 performance was weak, marked by declining sales, a significant drop in GAAP EPS, and a goodwill impairment. However, the strategic divestiture of the Feminine Care business for $340 million, coupled with a new $100 million share repurchase authorization and a commitment to return to organic sales growth in FY2026, suggests a clear path towards refocusing and potential future value creation. The Q4 organic sales growth and international market strength provide some positive momentum. Given the mixed results and the ongoing transformation, a 'Hold' recommendation is appropriate as investors await further clarity on the execution of the new strategy and the impact of the divestiture on the 2026 outlook.

Keywords

Edgewell Personal Care, EPC, Q4 2025 Earnings, Fiscal Year 2025 Results, 2026 Outlook, Feminine Care Divestiture, Personal Care, Consumer Products, Financial Results, Share Repurchase, Dividends, Organic Sales Growth, Gross Margin, Adjusted EPS, EBITDA, Restructuring, Goodwill Impairment, Schick, Wilkinson Sword, Billie, Edge, Skintimate, Playtex, Stayfree, Carefree, o.b., Banana Boat, Hawaiian Tropic, Bulldog, Jack Black, CREMO, Wet Ones